[Audit of the safety of hepatic arterial infusion of degradable starch microspheres (DSM). Adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer].
The purpose of this study was to clarify the safety of hepatic arterial infusion of degradable starch microspheres (DSM).adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer. A total of 19 patients who received this therapy (DSM: 600 mg or less, ADM: 30 mg, and MMC: 10 mg) three times or more every three weeks were included. Changes in laboratory data and frequency of the occurrence of the adverse effects were compared between patients aged 75 (n = 5) or more and those aged 74 or less (n = 14). There were no significant differences in changes in the leukocyte counts, AST, ALT, and c-reactive protein levels between the groups. The frequency of adverse effects also was not different between the groups. These results suggests that this therapy is feasible with acceptable safety even in patients aged 75 years or more.
Takeuchi
Ikuya
I
Dept. of Surgery, Saitama Medical Center, Saitama Medical School.
Ishida
Hideyuki
H
Kuwabara
Kouki
K
Hashimoto
Daijyo
D
Osada
Hisato
H
Kashimada
Akio
A
Matumoto
Yoshirou
Y
Miura
Tsuyoshi
T
D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001673:Biodegradation, Environmental; D015179:Colorectal Neoplasms / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008485:Medical Audit; D008863:Microspheres; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D012449:Safety; D013213:Starch / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin; D004317:Doxorubicin; D013213:Starch